AUGMENTIN 1gm In Skin And Soft Tissue Infection

Phase 4CompletedNCT00343135

GlaxoSmithKline195 enrolled

Overview

Study to evaluate the effects of AUGMENTIN 1gm in the treatment of Skin and Soft tissue infections

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

195

Conditions

Skin Diseases, Infectious Infection, Soft Tissue

Interventions

amoxicillin/clavulanate potassium 1gmDRUG

amoxicillin/clavulanate potassium 1gm

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * having diagnosed uncomplicated soft tissue infection (e.g furuncle, cellulitis) * has given freely documented consent. Exclusion Criteria: * antibiotics * have renal or hepatic insufficiency * systemic toxicity * pregnancy * lactation * hypersensitivity to penicillin or Beta-lactam antibiotics

Locations (3)

GSK Investigational Site

Karachi, Pakistan

GSK Investigational Site

Lahore, Pakistan

GSK Investigational Site

Lahore, Pakistan

Outcomes

Primary Outcomes

Clinical response at 10 - 14 days post therapy

Time frame: 10 - 14 days

Secondary Outcomes

Clinical response at on-therapy evaluation visit (2 - 4 days following initiation of therapy and 48 - 96 hours post therapy) Bacteriological response at (2 - 4 days following initiation of therapy, 48 - 96 hours post therapy, 10 - 14 days post therapy)

Time frame: 2 - 4 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.